4basebio PLC
4BB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £933 | £506 | £268 | £338 |
| % Growth | 84.4% | 88.8% | -20.7% | – |
| Cost of Goods Sold | £303 | £166 | £29 | £69 |
| Gross Profit | £630 | £340 | £239 | £269 |
| % Margin | 67.5% | 67.2% | 89.2% | 79.6% |
| R&D Expenses | £4,684 | £3,560 | £2,081 | £1,622 |
| G&A Expenses | £1,412 | £1,262 | £2,711 | £1,725 |
| SG&A Expenses | £1,765 | £1,542 | £2,956 | £1,857 |
| Sales & Mktg Exp. | £353 | £280 | £245 | £132 |
| Other Operating Expenses | £6,223 | £3,290 | £1,042 | £317 |
| Operating Expenses | £12,672 | £8,392 | £6,079 | £3,796 |
| Operating Income | -£12,042 | -£8,052 | -£5,840 | -£3,527 |
| % Margin | -1,290.7% | -1,591.3% | -2,179.1% | -1,043.5% |
| Other Income/Exp. Net | -£612 | -£302 | -£89 | -£113 |
| Pre-Tax Income | -£12,654 | -£8,354 | -£5,929 | -£3,640 |
| Tax Expense | -£321 | -£689 | -£779 | -£405 |
| Net Income | -£12,333 | -£7,665 | -£5,150 | -£3,235 |
| % Margin | -1,321.9% | -1,514.8% | -1,921.6% | -957.1% |
| EPS | -0.94 | -0.62 | -0.42 | -0.26 |
| % Growth | -51.6% | -47.6% | -61.5% | – |
| EPS Diluted | -0.94 | -0.62 | -0.42 | -0.26 |
| Weighted Avg Shares Out | 13,117 | 12,319 | 12,317 | 12,317 |
| Weighted Avg Shares Out Dil | 13,117 | 12,319 | 12,317 | 12,317 |
| Supplemental Information | – | – | – | – |
| Interest Income | £140 | £0 | £0 | £0 |
| Interest Expense | £752 | £302 | £89 | £113 |
| Depreciation & Amortization | £933 | £709 | £431 | £320 |
| EBITDA | -£10,969 | -£7,343 | -£5,409 | -£3,207 |
| % Margin | -1,175.7% | -1,451.2% | -2,018.3% | -948.8% |